Browse EX-10 agreements

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT

THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT (“Amendment”), effective as of March 2, 2026 (the “Amendment Effective Date”), is entered into and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (“WuXi Biologics”), and Korsana Biosciences, Inc., having its principal place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

ANTIBODY DISCOVERY AND OPTION AGREEMENT

THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is entered into and effective as of September 5, 2025 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parasa Holding LLC, a Delaware limited liability company (“Parasa”) and Korsa Biosciences, Inc., a Delaware corporation (“Korsa”). Paragon, Parasa and Korsa are also referred to herein individually as a “Party”, or collectively as the “Parties.”

RECITALS

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

CELL LINE LICENSE AGREEMENT

This Cell Line License Agreement (“Agreement”), effective as of December 2, 2024 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, “WuXi Biologics”) and KORSA Biosciences, Inc. a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”

The Parties agree as follows:

 

1.

Definitions

 

 

1.1

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

 

 

 

To:

Korsana Biosciences, Inc.

221 Crescent Street, Building 23, Suite 105

Waltham, MA 02453

Attn: Jonathan Violin, CEO

 

 

RE:

AOC Research Letter Agreement

April 3, 2026

Dear Jonathan,

…

PERFORMANCE STOCK UNIT GRANT NOTICE

 

Skillsoft Corp., a Delaware corporation (the “Company”), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the “Plan”), hereby grants to the Participant set forth below the number of Performance Stock Units set forth below (the “PSUs”). The PSUs are subject to all of the terms and conditions as set forth in this Performance Stock Unit Grant Notice (this “Grant Notice”), in the Performance Stock Unit Agreement (attached hereto), and in the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.

 

Participant: [*]

 

Date of Grant: [*]

 

Performance Period: [*]

 

Vesting Commencement Date: [*]

 

Target Number of Performance Stock Units: [*]

…

Privileged and Confidential

Subject to the Company’s Talent and Compensation Committee’s Approval

 

Corporate Office: 300 Innovative Way, Suite 201

Nashua, NH 03062 USA

skillsoft.com

O: +1-603-324-3000

 

 

May 20, 2026

 

John Frederick Via email

 

Dear John:

 

The purpose of this letter agreement (this “Agreement”) is to confirm the terms of the remainder of your employment with Skillsoft Corp. (the “Company”) and your retirement from the Company. Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Offer Letter between you and the Company dated as of May 15, 2025 (the “Offer Letter”).

 

1.           Transition Period and Retirement Date.

…

June 1, 2026

 

 

Scott Semel

Via Email

 

Dear Scott,

 

Per the terms of your offer letter with Skillsoft Corp. (the “Company”) dated November 17, 2025 (the “Offer Letter”), your employment may be extended beyond the Initial Term (as defined in the Offer Letter) by mutual agreement. This letter serves to acknowledge the extension of your employment term with the Company for an additional three months, from May 16, 2026 through August 16, 2026, inclusive (the “Extended Term”).

…

May 13, 2026

 

Ron Kisling

 

Re: Offer Letter

 

Dear Ron:

 

I am pleased to confirm the terms of our offer to you of employment with Skillsoft Corp. (“Skillsoft” or the “Company”), in the role of Chief Financial Officer, effective as of a date as determined by the Company’s Chief Executive Officer (the “Start Date”). This is a full-time, exempt position with the Company, reporting to me. This offer letter (the “Agreement”) memorializes the specific terms and conditions regarding our offer to you of employment with the Company. Unless specified otherwise, capitalized terms not defined herein shall have the respective meanings ascribed to them in Annex I, which is incorporated herein by reference.

 

Job Title:

Chief Financial Officer (CFO)

Reporting To:

Chief Executive Officer of the Company

Job

Responsibilities:

Duties and responsibilities customary for the role of CFO and as may reasonably be assigned to you consistent with your position.

Location:

…

turnermutualseparationag

1 MUTUAL SEPARATION AGREEMENT This Mutual Separation Agreement is made between: s MARY TURNER (“Employee”) and DESIGNER BRANDS INC. (the “Company”) (each referred to as a “Party” and collectively as the “Parties”) WHEREAS the Employee has been employed by the Company in the position of President – Canada, and commenced employment with the Company on or about September 26, 2016; AND WHEREAS the Parties have mutually expressed an interest to enter into this Mutual Separation Agreement and Release (the “Separation Agreement”) relating to the voluntary separation of the Employee’s employment from the Company, and the end of the Standard Executive Severance Agreement and any other employment offer/agreement, effective December 31, 2026 (the “Separation Date”); AND WHEREAS the Employee represents and confirms that she has not made, nor will she make, any claim for employment insurance benefits or other benefits relating to loss of employment with the Company for any period during which she is paid compensation by the Company pursuant to the Separation Agreement; A

…

​

SEPARATION AGREEMENT

​

This Separation Agreement (“Agreement”) is entered into on and effective on May 1, 2026 (the “Effective Date”) by and between Richard Wolfson (the “Executive”) and Cracker Barrel Old Country Store, Inc. (“Cracker Barrel” or the “Company”).

​

WHEREAS, the Executive is the Senior Vice President - General Counsel and Corporate Secretary for the Company;

​

WHEREAS, the Executive has previously notified the Company of his intent to retire;

​

WHEREAS, the Executive and the Company, with the approval of the Company’s Board of Directors (“Board”), wish to arrange for the Executive’s orderly separation from the Company in a manner that is mutually beneficial to the parties;

​

NOW, THEREFORE, in consideration of their respective concessions, releases and promises made hereunder, which consideration the parties acknowledge is adequate and sufficient for all purposes, and intending to be legally bound, the parties hereby agree as follows:

​

…

Document

Exhibit 10.1

ARCUTIS BIOTHERAPEUTICS, INC.

AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

This Arcutis Biotherapeutics, Inc. (the “Company”) Amended and Restated Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Equity Incentive Plan (the “Plan”) and shall be effective, as amended and restated herein, as of June 5, 2026 (the “Effective Date”). Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan.

Cash Compensation

Effective upon the Effective Date, annual retainers will be paid in the following amounts to Non-Employee Directors:

Board Service

Non-Employee Director

$

50,000 

Additional Board Service

Non-Executive Chair

$

40,000 

Additional Committee Service

Chair

Non-Chair

Audit Committee Member

$

20,000 

$

10,000 

Compensation Committee Member

$

18,000 

$

9,000 

Nominating and Corporate Governance Committee Member

$

10,000 

$

5,000

…

​

EXHIBIT 10.1

PURCHASE AND SALE AGREEMENT

(14939 Metcalf Avenue, Overland Park, Kansas 66223)

THIS PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into as of June 8, 2026 (the “Effective Date”), by and between 14939 METCALF AVE., LLC, a Texaslimited liability company (“Seller”), and MEDALIST DIVERSIFIED, INC., a Maryland corporation, or its assigns (collectively, “Buyer”). Seller and Buyer are each referred to herein as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, Seller is the owner of certain real property located at 14939 Metcalf Avenue, Overland Park, Kansas 66223, consisting of approximately 1.64 acres of land improved with a one-story automotive service building of approximately 16,100 square feet commonly known as the Caliber Collision, Overland Park, Kansas facility, as more particularly described on Exhibit A attached hereto (the “Land”);

…